Donald Trump Buys Shares of Insulet Corporation
Donald Trump disclosed a purchase of Insulet shares valued between $50,001 and $100,000.
Financial Disclosure Report
United States Congress • Office of Public Records • Washington, DC
Filer Information
- Name:
- Donald J Trump (R)
- Status:
- Member
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Insulet Corporation ($PODD) | Buy | May 22, 2026 | $50,001 - $100,000 |
Key Points
- Donald Trump purchased shares of Insulet Corporation, valued between $50,001 and $100,000, as reported on July 1, 2026.
- Insulet Corporation, a medical devices company, traded at $152.25 on Wednesday and has a market cap of about $10.5 billion.
- Analysts have varied opinions on Insulet, with price targets ranging from $165 to $360, and a consensus rating of strong buy.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Donald Trump, a prominent figure in the Republican Party, disclosed his purchase of Insulet Corporation shares, valued between $50,001 and $100,000. This transaction was reported under the STOCK Act, which mandates that members of Congress and certain executive officials disclose their stock trades.
Donald J Trump vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Insulet Corporation Stock Up 4.9%
Shares of NasdaqGS:PODD traded near $152.25 on Wednesday. Insulet Corporation, a company in the medical devices sector, has a market capitalization of approximately $10.5 billion. The stock's P/E ratio stands at 35.6, with a forward P/E of 18.8, indicating investor expectations of future earnings growth. Insulet's 52-week range is between $138.79 and $354.88, reflecting significant volatility. The company has a 50-day moving average of $159.13 and a 200-day moving average of $250.53, with a beta of 1.125, suggesting moderate market risk.
$PODD stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Insulet Corporation reported revenue of $2.9 billion, with a growth rate of 33.9%. The company achieved a net margin of 10.4% and return on equity of 23%. Earnings per share were $4.28. Investors can look forward to the next earnings report on August 6, 2026.
Insider Buying and Selling at Insulet Corporation
Several Insulet insiders were active in the market recently. On June 3, 2026, Timothy Stonesifer acquired 2,790 shares at an average price of $143.51, while Elizabeth Weatherman purchased 3,450 shares at $144.20. Additionally, on May 20, 2026, Luciana Borio, Timothy Scannell, and Robert Luther Huffines each bought 1,660 shares, although the transaction price was not specified.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank initiated coverage on Insulet with a 'buy' rating and a $190 price target. Truist Securities maintained its 'buy' rating with a $219 target on June 12, 2026. Citigroup, on May 28, 2026, held a 'hold' rating with a target of $165. Overall, the consensus among 24 analysts is a strong buy, with a mean price target of $240.25.
About Insulet Corporation
Insulet Corporation, headquartered in Acton, Massachusetts, is a healthcare company specializing in medical devices. It develops and sells insulin delivery systems for people with insulin-dependent diabetes. The company's flagship products include the Omnipod platform, which features automated insulin delivery systems and insulin management systems. Under the leadership of CEO Ashley A. McEvoy, Insulet employs around 5,400 people.
Bottom Line
Donald Trump's recent purchase of Insulet Corporation shares highlights the interest in this medical devices company. While the disclosed trade is backward-looking, it provides a glimpse into the investment activities of prominent figures. Investors will continue to monitor Insulet's performance, particularly given its strong earnings growth and analyst optimism.
Get Insulet Corporation alerts
New 13F filings, insider trades, and analyst moves on $PODD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.